Remote Dietary Counseling to Promote Healthy Diet and Blood Pressure
Remote Dietary Counseling Using Web-based Tools to Promote Healthy Diet and Blood Pressure (Healthy BP)
1 other identifier
interventional
187
1 country
2
Brief Summary
American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines recommend lifestyle modification for patients with elevated blood pressure. While eating a Dietary Approaches to Stop Hypertension (DASH)-type diet, increasing physical activity, and weight loss have been shown to reduce blood pressure, limited resources are available in the primary care setting to help patients make these changes. In this study, the investigators will compare the efficacy of a self-guided vs. dietitian-led approach using web-based lifestyle modification tools to reduce weight, improve dietary quality, and lower blood pressure in overweight/obese adults with elevated blood pressure.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2019
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 5, 2018
CompletedFirst Posted
Study publicly available on registry
October 9, 2018
CompletedStudy Start
First participant enrolled
January 16, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2021
CompletedJuly 28, 2021
July 1, 2021
2.5 years
October 5, 2018
July 27, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in 24-hour Systolic Blood Pressure
Measured by 24-hour ambulatory blood pressure monitoring (SpaceLabs Ontrak)
Baseline to 12-week follow-up
Secondary Outcomes (9)
Change in 24-hour diastolic blood pressure
Baseline to 12-week follow-up
Change in Daytime Systolic Blood Pressure
Baseline to 12-week follow-up
Change in Nighttime Systolic Blood Pressure
Baseline to 12-week follow-up
Change in Daytime Diastolic Blood Pressure
Baseline to 12-week follow-up
Change in Nighttime Diastolic Blood Pressure
Baseline to 12-week follow-up
- +4 more secondary outcomes
Other Outcomes (2)
Change in individual components of Healthy Eating Index score
Baseline to 12-week follow-up
Satisfaction with the Healthy BP Research Study
12-week follow-up
Study Arms (2)
Self-Guided Approach
ACTIVE COMPARATORIn the self-guided arm, participants will receive access to web-based tools to help achieve healthy lifestyle changes to lower their blood pressure. The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry.
Dietitian-led Approach
EXPERIMENTALIn the dietitian-led arm, dietitian will use motivational interviewing in 15-30 minute telephone calls with participants. The web-based tools include: 1) a web-based food frequency questionnaire (Viocare FFQ), which will provide a snapshot of participants' dietary habits in the past 6 months as well as personalized recommendations for areas to improve; 2) access to an evidence-based program (Evolve, formerly BMIQ), which includes program materials for weight loss and leading a healthy lifestyle as well as the ability for capturing dietary data entry. The web platform will be used to share participant dietary and weight data with dietitians.
Interventions
For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information. From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform. In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform.
For a 12-week period, patients will be asked to access the web platform (Evolve, formerly BMIQ), review educational materials, and enter dietary information. From January 2019 to February 2021, participants used an earlier version of the platform, which was used in tandem with LoseIt (www.loseit.com), a meal-logging app that integrated with the platform. In February 2021, a platform update occurred (Evolve) where the core tenets of the program remained the same and included the dietary data entry directly on the platform. Dietitians will access the web platform and provided personalized motivational interview phone calls on a weekly basis.
Eligibility Criteria
You may qualify if:
- hour ambulatory SBP 120-160 mmHg
- BMI ≥ 25 kg/m2
- Access to a telephone
- Access to a computer or smartphone with internet access
- Complete dietary data entry for at least 5 out of 7 days during run-in period
- Enter weight into the platform during run-in period
You may not qualify if:
- Inability to understand English
- Myocardial infarction, stroke, or atherosclerotic cardiovascular disease procedure within last 6 months.
- Current treatment for malignancy
- Planned or previous bariatric surgery
- Pregnant, breast-feeding, or planned pregnancy prior to the end of participation
- Self-reported average consumption of \> 21 alcoholic beverages per week or binge drinking.
- Psychiatric hospitalization in past year
- Current symptoms of angina
- Planning to leave the area prior to end of the study
- Current participation in another clinical trial
- Principal investigator discretion (i.e. concerns about safety, compliance)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Geisinger Cliniclead
Study Sites (2)
Geisinger Medical Center
Danville, Pennsylvania, 17822, United States
Geisinger Wyoming Valley
Wilkes-Barre, Pennsylvania, 18711, United States
Related Publications (2)
Chang AR, Gummo L, Yule C, Bonaparte H, Collins C, Naylor A, Appel LJ, Juraschek SP, Bailey-Davis L. Effects of a Dietitian-Led, Telehealth Lifestyle Intervention on Blood Pressure: Results of a Randomized, Controlled Trial. J Am Heart Assoc. 2022 Oct 4;11(19):e027213. doi: 10.1161/JAHA.122.027213. Epub 2022 Sep 29.
PMID: 36172955DERIVEDTaher M, Yule C, Bonaparte H, Kwiecien S, Collins C, Naylor A, Juraschek SP, Bailey-Davis L, Chang AR. Telehealth versus self-directed lifestyle intervention to promote healthy blood pressure: a protocol for a randomised controlled trial. BMJ Open. 2021 Mar 3;11(3):e044292. doi: 10.1136/bmjopen-2020-044292.
PMID: 33658261DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alexander Chang, MD
Geisinger Clinic
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 5, 2018
First Posted
October 9, 2018
Study Start
January 16, 2019
Primary Completion
June 30, 2021
Study Completion
June 30, 2021
Last Updated
July 28, 2021
Record last verified: 2021-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
- Time Frame
- Data will become available at the time of publication of the main trial results and will be publicly available indefinitely.
- Access Criteria
- The deidentified IPD will be publicly available without restrictions.
The study protocol, statistical analysis plan, informed consent form, analytic code, and clinical study report will be shared at the time of publication of the main trial results; these data will be deidentified. These data will be publicly available indefinitely.